LLY

755.74

-0.21%↓

JNJ

152.57

+0.85%↑

UNH

315.59

+8.36%↑

ABBV

185.7

+0.95%↑

NVO

66.94

+4.04%↑

LLY

755.74

-0.21%↓

JNJ

152.57

+0.85%↑

UNH

315.59

+8.36%↑

ABBV

185.7

+0.95%↑

NVO

66.94

+4.04%↑

LLY

755.74

-0.21%↓

JNJ

152.57

+0.85%↑

UNH

315.59

+8.36%↑

ABBV

185.7

+0.95%↑

NVO

66.94

+4.04%↑

LLY

755.74

-0.21%↓

JNJ

152.57

+0.85%↑

UNH

315.59

+8.36%↑

ABBV

185.7

+0.95%↑

NVO

66.94

+4.04%↑

LLY

755.74

-0.21%↓

JNJ

152.57

+0.85%↑

UNH

315.59

+8.36%↑

ABBV

185.7

+0.95%↑

NVO

66.94

+4.04%↑

Search

Kura Oncology Inc

Gesloten

SectorGezondheidszorg

6.22 3.49

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

5.92

Max

6.29

Belangrijke statistieken

By Trading Economics

Inkomsten

-38M

-57M

Verkoop

-40M

14M

EPS

-0.66

Winstmarge

-407.067

Werknemers

192

EBITDA

-48M

-65M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+275.42% upside

Dividenden

By Dow Jones

Volgende Winsten

7 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.4M

527M

Vorige openingsprijs

2.73

Vorige sluitingsprijs

6.22

Nieuwssentiment

By Acuity

22%

78%

50 / 382 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Kura Oncology Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

19 mei 2025, 20:40 UTC

Acquisities, Fusies, Overnames

FedEx Names CEO, Chairman for Planned Freight Spinoff

20 mei 2025, 00:00 UTC

Top Nieuws

America's Fiscal Situation Threatens the Good Mood on Wall Street -- WSJ

19 mei 2025, 23:48 UTC

Marktinformatie

Nikkei May Rise as Fears About Moody's U.S. Downgrade Ease -- Market Talk

19 mei 2025, 23:43 UTC

Marktinformatie

Gold Edges Lower on Possible Technical Correction -- Market Talk

19 mei 2025, 22:33 UTC

Marktinformatie

Uranium Buyers Could Accelerate Restocking -- Market Talk

19 mei 2025, 22:16 UTC

Acquisities, Fusies, Overnames

Yuexiu Property to Use Divestment Proceeds for Business Development Purposes

19 mei 2025, 22:16 UTC

Acquisities, Fusies, Overnames

Yuexiu Property to Sell Stake for CNY4.15B

19 mei 2025, 22:15 UTC

Acquisities, Fusies, Overnames

Yuexiu Property to Sell Stake to China Resources Land

19 mei 2025, 22:15 UTC

Acquisities, Fusies, Overnames

Yuexiu Property to Sell 65% Stake in Beijing Haizhen Real Estate

19 mei 2025, 22:02 UTC

Winsten

Trip.com Group 1Q Rev $1.9B >TCOM

19 mei 2025, 22:02 UTC

Winsten

Trip.com Group 1Q Adj EPS 82c >TCOM

19 mei 2025, 22:02 UTC

Winsten

Trip.com Group 1Q EPS 84c >TCOM

19 mei 2025, 21:58 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

19 mei 2025, 21:58 UTC

Marktinformatie

Global Equities Roundup: Market Talk

19 mei 2025, 21:58 UTC

Marktinformatie

Automakers to Raise Prices by End of June, Toyota COO Says -- Market Talk

19 mei 2025, 21:50 UTC

Winsten

Home Depot's Earnings Could Mirror a Sluggish Housing Market -- Barrons.com

19 mei 2025, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

19 mei 2025, 20:21 UTC

Acquisities, Fusies, Overnames

FedEx: R. Brad Martin, Vice Chmn of the FedEx Corp. Bd of Directors, Agreed to Serve as Chmn of the Bd of FedEx Freight >FDX

19 mei 2025, 20:21 UTC

Acquisities, Fusies, Overnames

FedEx: Both Appointments Will Be Effective Upon Completion of the Previously Announced Separation of FedEx Freight From FedEx Corp. >FDX

19 mei 2025, 20:21 UTC

Acquisities, Fusies, Overnames

FedEx: Plans for the Spinoff, Which Is Expected to Occur by June 2026, Remain on Track >FDX

19 mei 2025, 20:21 UTC

Acquisities, Fusies, Overnames

FedEx: Announces Leadership for Independent FedEx Freight Co Upon Separation

19 mei 2025, 20:21 UTC

Acquisities, Fusies, Overnames

FedEx: John A. Smith, Oper Chief, U.S. and Canada, of Federal Express, Has Been Selected as Pres and CEO of FedEx Freight >FDX

19 mei 2025, 20:20 UTC

Top Nieuws

Major U.S. Stock Indexes Finish Higher; Dollar Falls -- WSJ

19 mei 2025, 20:15 UTC

Acquisities, Fusies, Overnames

U.S. Steel Stock Rises on Report of Better Nippon Offer. Why Trump Could Say 'Yes.' -- Barrons.com

19 mei 2025, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

19 mei 2025, 19:59 UTC

Top Nieuws

JPMorgan CEO Dimon Still Intends to Step Down in Next Few Years. 'It's Up to the Board.' -- Barrons.com

19 mei 2025, 19:58 UTC

Marktinformatie

Estonia Redirects Ships After Russia Detains Greek Tanker -- Market Talk

19 mei 2025, 19:52 UTC

Marktinformatie

Imports Accelerate at Southern California Ports -- Market Talk

19 mei 2025, 19:16 UTC

Marktinformatie

Oil Futures Edge Up After Shaky Start -- Market Talk

19 mei 2025, 19:00 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

Sanmina Shares Fall After Deal to Buy AMD's Newly Acquired Manufacturing Company

Peer Vergelijking

Prijswijziging

Kura Oncology Inc Prognose

Koersdoel

By TipRanks

275.42% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 22.6 USD  275.42%

Hoogste 40 USD

Laagste 10 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Kura Oncology Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

13 ratings

10

Buy

3

Hold

0

Sell

Technische score

By Trading Central

5.575 / 6.6Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

50 / 382 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.